SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors discuss upcoming earnings and the potential for a stock split, with community sentiments ranging from bullish expectations of significant growth to concerns about high valuation and downside risk. Discussions also involve the company's AI capabilities, partnerships, and broader market conditions, with some comparing it to other high-growth tech companies. Traders are actively strategizing around options and earnings reactions.

Superfruits AI is redefining the Web3 landscape with an ecosystem of fruit-themed AI agents offering specialized insights and services, ranging from blockchain security to market sentiment analysis. Building on this vibrant foundation, we're introducing groundbreaking features like a proprietary Web3-trained AI model, an interactive Virtual Research Room, and the innovative concept of "Juices." These "Juices" empower high token holders to mix and match agents' capabilities, creating custom virtual rooms where agents collaborate on tailored analyses for portfolios or projects. By blending cutting-edge AI with gamified user experiences, Superfruits AI positions itself as a pioneer in Web3 analytics, offering unique tools that not only secure but also enrich the decentralized journey for every user.

SuperFruits AI

SuperFruits AI ($SUPAI) is trending as community members discuss its potential breakout and strong chart structure, with many highlighting its resilience amidst broader crypto market fluctuations. Conversations suggest an accumulation phase and anticipation for a significant move, emphasizing the intersection of AI technology and cryptocurrency. The community is closely watching volume and technical indicators, pointing towards growing interest from smart money.

Solana Street Bets is not just a memecoin; it's a symbol of creativity, humor, and the power of a united community. Inspired by the infamous /wallstreetbets subreddit. Solana Street Bets is here to put respect on the Wall St originated memes in the industry. Solana Street Bets is a decentralized Solana meme coin inspired by the infamous /wallstreetbets subreddit.

SatoshiStreetBets

SatoshiStreetBets ($SSB) is gaining attention as the community anticipates its listing on BitMart, with discussions around staking rewards and potential future developments. Community members are also actively debating the project's legitimacy, with some labeling it a scam while others express strong belief in its long-term potential. The recent price action and roadmap, including a proposed ETH bridge, are key talking points among investors.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending amidst discussions about its correlation to Ethereum's price movements and overall crypto market sentiment. Community members are debating whether BMNR is a worthwhile investment compared to direct ETH ownership, with some expressing concerns about potential dilution and the effectiveness of its treasury strategy. Tom Lee's influence and past price predictions are also being heavily scrutinized.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as investors discuss the company's potential rebound in the EV sector, driven by improving fundamentals and expansion plans. Community talking points include NIO's unmatched battery-swap network, recurring revenue from Battery-as-a-Service (BaaS), and management's reiterated goal of achieving profitability. The focus is on NIO's expansion of premium and mass-market models, positioning it for significant growth by 2026.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

RIGL is trending as the community discusses its potential for an earnings surprise and the possibility of a buyout, fueled by strong sales and a low PE ratio. Community members are closely watching for news that could drive the stock higher, including potential partnerships and FDA approvals. Some traders are debating whether the stock is overbought, while others point to its strong fundamentals and growth potential.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin's price volatility has traders on edge, with liquidations and potential market manipulation being hot topics. Community sentiment is mixed, with some anticipating a rally while others foresee a significant pullback, leading to debates about long-term holding versus short-term trading strategies. The broader discussion includes the impact of institutional investors and potential regulatory changes on Bitcoin's future.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is gaining attention as it attempts to break out of a multi-year consolidation, with community members closely watching key resistance levels. Bullish sentiment is fueled by trade deal optimism and potential Fed rate cuts, while others remain cautious due to narrow market breadth and economic uncertainties. Discussions revolve around whether small caps can sustain upward momentum or if a pullback is imminent.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is trending amidst discussions around potential acquisitions and strategic moves to strengthen its position in the hereditary angioedema (HAE) market. The community is weighing the implications of acquiring Astria Therapeutics and is actively debating whether this is a sound strategy. Some view the move as a way to solidify market dominance, while others express concerns about potential dilution and increased debt.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific is trending due to Roth Capital and Macquarie issuing buy ratings and price target increases, with community members speculating on the potential upside following a deal collapse with CoreWeave. The community is actively discussing Core Scientific's AI/HPC infrastructure pipeline and its low-cost power edge, as well as potential trading halts on platforms like Robinhood. Bullish sentiment is building, with some anticipating further rallies and increased valuations in the AI infrastructure sector.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

3 Cancer-Focused Stocks Showing Strong Pipeline Progress

Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.

<ul class="summary-bullets"><li>Verastem reported early trial data showing its experimental oral therapy targeting KRAS-driven cancers was well-tolerated, with no severe gastrointestinal side effects.</li><li>Four of five evaluable patients showed tumor reduction, prompting optimism around the drug’s potential for pancreatic and colorectal cancer treatment.</li><li>Retail traders on Stocktwits responded enthusiastically, calling the update an example of improved, patient-focused design and praising the drug’s tumor-reducing effects.</li></ul>Verastem Oncology shares drew heavy retail chatter on Thursday after the company reported encouraging early results from its Phase 1/2a trial of VS-7375, an investigational oral KRAS G12D inhibitor targeting hard-to-treat solid tumors such as pancreatic and colorectal cancers.<h2 class="st-heading-2">Early Safety Data And Tumor Response</h2>The company said the first two monotherapy dose levels of 400 mg and 600 mg once daily&nbsp;were cleared with no dose-limiting toxicities, and no nausea, vomiting, or diarrhea above Grade 1 was observed. Of the five patients evaluable for efficacy, four experienced tumor reduction and remain on treatment.“Preliminary safety and tolerability data suggest VS-7375 can be administered at efficacious doses while effectively managing gastrointestinal side effects,” said CEO Dan Paterson, adding that the company is seeing “anti-tumor activity among pre-treated patients with advanced pancreatic cancer and other solid tumors.”<h2 class="st-heading-2">Combination Study Now Enrolling</h2>With monotherapy dose escalation continuing to 900 mg, Verastem said it has begun enrolling patients in a combination cohort testing VS-7375&nbsp;with cetuximab in KRAS G12D-mutant solid tumors, including colorectal cancer.Verastem’s Chief Medical Officer John Hayslip said the company is encouraged by the drug’s tolerability and early signs of anti-tumor activity, adding that the ongoing combination trial with cetuximab addresses “a significant unmet need for treatments specifically targeting KRAS G12D-mutant cancers.”The company plans to report an interim safety and efficacy update in the first half of 2026 and expand the trial globally following dose optimization.<h2 class="st-heading-2">Background On The Candidate</h2>VS-7375 is the lead program from Verastem’s collaboration with GenFleet Therapeutics, which is running a parallel study in China under the name GFH375. GenFleet previously selected 600 mg once daily as the recommended Phase 2 dose, citing similar safety and response patterns.The KRAS G12D mutation accounts for 26% of all KRAS mutations and is most prevalent in pancreatic, colorectal, endometrial, and lung cancers, which&nbsp;have few or no targeted treatment options.<h2 class="st-heading-2">Stocktwits Bulls Cheer Early Trial Results</h2>On Stocktwits, retail sentiment for Verastem was ‘extremely bullish’ amid a 123% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:967/134;" src="https://news.stocktwits-cdn.com/vstm_ss_jpg_a440d5807e.webp" alt="vstm ss.jpg" width="967" height="134"><figcaption>VSTM sentiment and message volume as of October 23 | Source: Stocktwits</figcaption></figure>One user said they were encouraged by Verastem’s latest update, calling it an example of how small refinements in trial design and dosing can meaningfully improve patient experience and tolerability.<stembedurl>https://stocktwits.com/CrozrX/message/633534378</stembedurl>Another user expressed optimism about Verastem, noting that the drug appeared to reduce tumor size while causing limited side effects.<stembedurl>https://stocktwits.com/UWilDue0/message/633520498</stembedurl><a href="https://stocktwits.com/symbol/VSTM">Verastem’s stock</a> has risen 51% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Verastem Oncology logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Verastem Stock Ignites Retail Buzz After Early Cancer Drug Data Show Tumor Reduction, Mild Side Effects

Four of five evaluable patients showed tumor reduction, prompting optimism around the drug’s potential for pancreatic and colorectal cancer treatment.

Equity

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced encouraging preliminary data from...

Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Verastem (VSTM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a...

Best Momentum Stocks to Buy for Oct. 21

VSTM, AS and SOTK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 21, 2025.

New Strong Buy Stocks for Oct. 21: NEM, AS and More

NEM, RY, AS, VSTM and SOTK have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 21, 2025.

Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice

Does Verastem (VSTM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet

The mean of analysts' price targets for Verastem (VSTM) points to a 68.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, updated efficacy and...

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$9.45
Prev Close	$9.23
Open	$9.22
Dividend Yield	0.00%
50-Day Moving Average	$9.09
Beta	1.47
Avg. Volume	2.16M
PE Ratio	-2.69

52-Week High	$11.25
52-Week Low	$3.46
Market Capitalization	$581.6M
EPS (Annual)	-$3.66
Price to Book	16.12
Revenue Per Employee	$128,205.13
Enterprise Value/EBITDA	N/A

VSTM
Verastem Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VSTM News

VSTMVerastem Inc